| Website | caratherapeutics.com |
| Category | BioTech |
| Phone | 203-567-1500 |
| info@caratherapeu... | |
| Employees |
| TOTAL | $38.7M |
| FUNDING TOTAL | $38.7M |
| Series B, 12/05 Ascent Biomedical Ventures Esperante Ventures | $4.7M |
| Series C, 11/06 MVM Life Science Partners Alta Partners Ascent Biomedical Ventures | $19M |
| Series D, 7/10 Rho Capital Partners Alta Partners Connecticut Innovations MVM Life Science Partners Mitsubishi Corporation Scottish Widows Investment Partnership Ascent Biomedical Ventures Devon Park BioVentures | $15M |
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
